SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Ya-Nan Xing, Peng Deng, Hui-Mian Xu, Canstatin induces apoptosis in gastric cancer xenograft growth in mice through the mitochondrial apoptotic pathway, Bioscience Reports, 2014, 34, 2, 189

    CrossRef

  2. 2
    Nils Nicolay, Klaus Herfarth, Cetuximab zusätzlich zur Radiochemotherapie?, Info Onkologie, 2014, 17, 2, 25

    CrossRef

  3. 3
    Y.-M. Guo, W.-W. Yu, M. Zhu, C.-Y. Guo, Clinicopathological and prognostic significance of epidermal growth factor receptor overexpression in patients with esophageal adenocarcinoma: a meta-analysis, Diseases of the Esophagus, 2014, 27, 5
  4. 4
    Yogesh K. Vashist, Florian Trump, Florian Gebauer, Asad Kutup, Cenap Güngör, Viacheslav Kalinin, Rather Muddasar, Eik Vettorazzi, Emre F. Yekebas, Burkhard Brandt, Klaus Pantel, Jakob R. Izbicki, EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer, Targeted Oncology, 2014, 9, 1, 43

    CrossRef

  5. 5
    Susan J Dutton, David R Ferry, Jane M Blazeby, Haider Abbas, Asa Dahle-Smith, Wasat Mansoor, Joyce Thompson, Mark Harrison, Anirban Chatterjee, Stephen Falk, Angel Garcia-Alonso, David W Fyfe, Richard A Hubner, Tina Gamble, Lynnda Peachey, Mina Davoudianfar, Sarah R Pearson, Patrick Julier, Janusz Jankowski, Rachel Kerr, Russell D Petty, Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial, The Lancet Oncology, 2014, 15, 8, 894

    CrossRef

  6. 6
    Sing Yu Moorcraft, Ian Chau, Investigational therapies targeting the ErbB family in oesophagogastric cancer, Expert Opinion on Investigational Drugs, 2014, 1

    CrossRef

  7. 7
    N.H. Nicolay, K. Herfarth, Zusatz von Cetuximab zur primären Radiochemotherapie von Ösophaguskarzinomen verursacht schlechteres Gesamtüberleben, Strahlentherapie und Onkologie, 2014, 190, 2, 233

    CrossRef

  8. 8
    Vinayak Nagaraja, Guy D Eslick, Advances in biomarkers for esophageal cancer, Expert Review of Anticancer Therapy, 2013, 13, 10, 1169

    CrossRef

  9. 9
    Anna L Paterson, Maria O'Donovan, Elena Provenzano, Liam J Murray, Helen G Coleman, Brian T Johnson, Damian T McManus, Marco Novelli, Laurence B Lovat, Rebecca C Fitzgerald, Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis, The Journal of Pathology, 2013, 230, 1
  10. 10
    Thomas Crosby, Christopher N Hurt, Stephen Falk, Simon Gollins, Somnath Mukherjee, John Staffurth, Ruby Ray, Nadim Bashir, John A Bridgewater, J Ian Geh, David Cunningham, Jane Blazeby, Rajarshi Roy, Tim Maughan, Gareth Griffiths, Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial, The Lancet Oncology, 2013, 14, 7, 627

    CrossRef

  11. 11
    Ramaswamy Pandilla, Viswakalyan Kotapalli, Swarnalata Gowrishankar, MohanaVamsy Chigurupati, Sujith Patnaik, Shantveer Uppin, Subramanyeshwar Rao, NarasimhaRaju Kalidindi, Sastry Regulagadda, Challa Sundaram, Mukta Srinivasulu, Anjayneyulu Vasala, Murali Dharan Bashyam, Distinct genetic aberrations in oesophageal adeno and squamous carcinoma, European Journal of Clinical Investigation, 2013, 43, 12
  12. 12
    Marcus Bettstetter, Sabina Berezowska, Gisela Keller, Axel Walch, Annette Feuchtinger, Julia Slotta-Huspenina, Marcus Feith, Enken Drecoll, Heinz Höfler, Rupert Langer, Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN, and KRAS/NRAS/BRAF in primary resected esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome, Human Pathology, 2013, 44, 5, 829

    CrossRef

  13. 13
    Patrick M. Boland, Barbara Burtness, Esophageal carcinoma, Current Opinion in Oncology, 2013, 25, 4, 417

    CrossRef

  14. 14
    Romana Illig, Eckhard Klieser, Tobias Kiesslich, Daniel Neureiter, GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?, Gastroenterology Research and Practice, 2013, 2013, 1

    CrossRef

  15. 15
    Guilherme Pretto, Richard Ricachenevsky Gurski, Marcelo Binato, Daniel Navarini, Wolfgan William Schmidt Aguiar, Luise Meurer, Increase of Epidermal Growth Factor Receptor Expression in Progression of GERD, Barrett, and Adenocarcinoma of Esophagus, Digestive Diseases and Sciences, 2013, 58, 1, 115

    CrossRef

  16. 16
    Monica Dandona Desai, Bikramajit Singh Saroya, Albert Craig Lockhart, Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) family in GI cancers, Expert Opinion on Investigational Drugs, 2013, 22, 3, 341

    CrossRef

  17. 17
    Esther Cidon, Sara Ellis, Yasir Inam, Sola Adeleke, Sara Zarif, Tom Geldart, Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy, Cancers, 2013, 5, 1, 64

    CrossRef

  18. 18
    Nicholas J Clemons, Wayne A Phillips, Reginald V Lord, Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction, Cancer Biology & Therapy, 2013, 14, 9, 782

    CrossRef

  19. 19
    Thomas C. Wehler, Swaantje Hamdi, Annett Maderer, Claudine Graf, Ines Gockel, Irene Schmidtmann, Michael Hainz, Martin R. Berger, Matthias Theobald, Peter R. Galle, Markus Moehler, Carl C. Schimanski, Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft—no benefit of combination therapy, International Journal of Colorectal Disease, 2013, 28, 3, 385

    CrossRef

  20. 20
    Miao-zhen Qiu, Rui-hua Xu, The progress of targeted therapy in advanced gastric cancer, Biomarker Research, 2013, 1, 1, 32

    CrossRef

  21. 21
    David J. Adelstein, Cristina P. Rodriguez, Lisa A. Rybicki, Denise I. Ives, Thomas W. Rice, A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction, Investigational New Drugs, 2012, 30, 4, 1684

    CrossRef

  22. 22
    Xuping Wu, Håkan Hedman, Michael Bergqvist, Stefan Bergström, Roger Henriksson, Joachim Gullbo, Johan Lennartsson, Patrik Hesselius, Simon Ekman, Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity, Acta Oncologica, 2012, 51, 1, 69

    CrossRef

  23. 23
    Vivianda Menke, Raymond GJ Pot, Leon MG Moons, Katinka PM van Zoest, Bettina Hansen, Herman van Dekken, Peter D Siersema, Johannes G Kusters, Ernst J Kuipers, Functional single-nucleotide polymorphism of epidermal growth factor is associated with the development of Barrett's esophagus and esophageal adenocarcinoma, Journal of Human Genetics, 2012, 57, 1, 26

    CrossRef

  24. 24
    Takashi Oshima, Munetaka Masuda, Molecular targeted agents for gastric and gastroesophageal junction cancer, Surgery Today, 2012, 42, 4, 313

    CrossRef

  25. 25
    Mohamedtaki A. Tejani, Barbara A. Burtness, Multi-Modality Therapy for Cancer of the Esophagus and GE Junction, Current Treatment Options in Oncology, 2012, 13, 3, 390

    CrossRef

  26. 26
    Emma H. Allott, Elizabeth Oliver, Joanne Lysaght, Steven G. Gray, John V. Reynolds, Helen M. Roche, Graham P. Pidgeon, The SGBS cell strain as a model for the in vitro study of obesity and cancer, Clinical and Translational Oncology, 2012, 14, 10, 774

    CrossRef

  27. 27
    Qi-min Zhan, Lu-hua Wang, Yong-mei Song, Yun-wei Ou, Jing Jiang, Jing Fan, Jing-bo Wang, Jie Shen, Recent Advances in Cancer Research and Therapy, 2012,

    CrossRef

  28. 28
    Khaldoun Almhanna, Current Challenges in Personalized Cancer Medicine, 2012,

    CrossRef

  29. 29
    David H. Ilson, David Kelsen, Manish Shah, Gary Schwartz, Douglas A. Levine, Jeff Boyd, Marinela Capanu, Benjamin Miron, David Klimstra, A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus, Cancer, 2011, 117, 7
  30. 30
    Sheela Rao, Lyndsey Welsh, David Cunningham, Robert H. te-Poele, Martin Benson, Andrew Norman, Claire Saffery, Ian Giddings, Paul Workman, Paul A. Clarke, Correlation of Overall Survival With Gene Expression Profiles in a Prospective Study of Resectable Esophageal Cancer, Clinical Colorectal Cancer, 2011, 10, 1, 48

    CrossRef

  31. 31
    James Cronin, Elizabeth McAdam, Antonios Danikas, Chris Tselepis, Paul Griffiths, John Baxter, Linzi Thomas, James Manson, Gareth Jenkins, Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in High-Grade Dysplasia and Adenocarcinoma of the Esophagus and May Represent a Biomarker of Histological Progression in Barrett's Esophagus (BE), The American Journal of Gastroenterology, 2011, 106, 1, 46

    CrossRef

  32. 32
    Tadahiro Nozoe, Emiko Mori, Tomohiro Iguchi, Akinori Egashira, Eisuke Adachi, Akito Matsukuma, Takahiro Ezaki, Immunohistochemical expression of epidermal growth factor receptor in breast cancer, Breast Cancer, 2011, 18, 1, 37

    CrossRef

  33. 33
    Qiong Zhao, Jianzhong Shentu, Nong Xu, Jianya Zhou, Guangdie Yang, Yinan Yao, Fenlai Tan, Dongyang Liu, Yingxiang Wang, Jianying Zhou, Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors, Lung Cancer, 2011, 73, 2, 195

    CrossRef

  34. 34
    Z A Wainberg, L-S Lin, B DiCarlo, K M Dao, R Patel, D J Park, H-J Wang, R Elashoff, N Ryba, J R Hecht, Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction, British Journal of Cancer, 2011, 105, 6, 760

    CrossRef

  35. 35
    Alicia Okines, David Cunningham, Ian Chau, Targeting the human EGFR family in esophagogastric cancer, Nature Reviews Clinical Oncology, 2011, 8, 8, 492

    CrossRef

  36. 36
    Cristina P. Rodriguez, David J. Adelstein, Thomas W. Rice, Lisa A. Rybicki, Gregory M. M. Videtic, Jerrold P. Saxton, Sudish C. Murthy, David P. Mason, Denise I. Ives, A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer, Journal of Thoracic Oncology, 2010, 5, 2, 229

    CrossRef

  37. 37
    Kaushik Mukherjee, A. Bapsi Chakravarthy, Laura W. Goff, Wael El-Rifai, Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy, Digestive Diseases and Sciences, 2010, 55, 12, 3304

    CrossRef

  38. 38
    Anna Isinger-Ekstrand, Jan Johansson, Mattias Ohlsson, Princy Francis, Johan Staaf, Mats Jönsson, Åke Borg, Mef Nilbert, Genetic profiles of gastroesophageal cancer: combined analysis using expression array and tiling array–comparative genomic hybridization, Cancer Genetics and Cytogenetics, 2010, 200, 2, 120

    CrossRef

  39. 39
    Andreas H Marx, Margarete Zielinski, Charlotte-Marie Kowitz, Ana-Maria Dancau, Sabrina Thieltges, Ronald Simon, Matthias Choschzick, Emre Yekebas, Jussuf T Kaifi, Martina Mirlacher, Djordje Atanackovic, Tim H Brümmendorf, Walter Fiedler, Carsten Bokemeyer, Jakob R Izbicki, Guido Sauter, Homogeneous EGFR amplification defines a subset of aggressive Barrett’s adenocarcinomas with poor prognosis, Histopathology, 2010, 57, 3
  40. 40
    Carl C. Schimanski, Tim Zimmermann, Irene Schmidtmann, Ines Gockel, Hauke Lang, Peter R. Galle, Markus Moehler, Martin R. Berger, K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRα in colorectal cancer, International Journal of Colorectal Disease, 2010, 25, 2, 181

    CrossRef

  41. 41
    F. Lordick, S. Lorenzen, Systemtherapie des Ösophaguskarzinoms und Stellenwert zielgerichteter Substanzen, Der Onkologe, 2010, 16, 5, 515

    CrossRef

  42. 42
    Ananya Das, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  43. 43
    S. Lorenzen, T. Schuster, R. Porschen, S.-E. Al-Batran, R. Hofheinz, P. Thuss-Patience, M. Moehler, P. Grabowski, D. Arnold, T. Greten, L. Muller, N. Rothling, C. Peschel, R. Langer, F. Lordick, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie, Annals of Oncology, 2009, 20, 10, 1667

    CrossRef

  44. 44
    Jaume Capdevila, Francisco Javier Ramos, Teresa Macarulla, Elena Elez, Manuel Ruiz-Echarri, Jose Perez-Garcia, Josep Tabernero, Development of new drug strategies in infrequent digestive tumors: esophageal, biliary tract, and anal cancers, Current Opinion in Oncology, 2009, 21, 4, 374

    CrossRef

  45. 45
    Sarah Morgan, Jennifer R. Grandis, ErbB receptors in the biology and pathology of the aerodigestive tract, Experimental Cell Research, 2009, 315, 4, 572

    CrossRef

  46. 46
    William H. Fiske, David Threadgill, Robert J. Coffey, ERBBs in the gastrointestinal tract: Recent progress and new perspectives, Experimental Cell Research, 2009, 315, 4, 583

    CrossRef

  47. 47
    X Wu, A Wanders, P Wardega, B Tinge, L Gedda, S Bergstrom, L Sooman, J Gullbo, M Bergqvist, P Hesselius, J Lennartsson, S Ekman, Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin, British Journal of Cancer, 2009, 100, 2, 334

    CrossRef

  48. 48
    Yixing Jiang, Eric Kimchi, Jaffer A Ajani, Localized squamous cell carcinoma of the esophagus: bimodality or trimodality approach?, Future Oncology, 2009, 5, 2, 157

    CrossRef

  49. 49
    Toshihiko Doi, Atsushi Ohtsu, Makoto Tahara, Tomohide Tamura, Kuniaki Shirao, Yasuhide Yamada, Satoru Otani, Bing-Bing Yang, Masayuki Ohkura, Tomoko Ohtsu, Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors, International Journal of Clinical Oncology, 2009, 14, 4, 307

    CrossRef

  50. You have free access to this content50
    M A Kim, H S Lee, H E Lee, Y K Jeon, H K Yang, W H Kim, EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number, Histopathology, 2008, 52, 6
  51. 51
    C. Hennequin, L. Quero, V. Baruch-Hennequin, C. Maylin, Faut-il encore opérer les cancers de l’œsophage localement évolués ?, Cancer/Radiothérapie, 2008, 12, 8, 831

    CrossRef

  52. 52
    Harry H Yoon, Arlene A Forastiere, Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome, Future Oncology, 2008, 4, 3, 413

    CrossRef

  53. 53
    Ying Cao, Yong Li, Marcia Edelweiss, Banu Arun, Daniel Rosen, Erika Resetkova, Yun Wu, Jinsong Liu, Aysegul Sahin, Constance T. Albarracin, Loss of Annexin A1 Expression in Breast Cancer Progression, Applied Immunohistochemistry & Molecular Morphology, 2008, 16, 6, 530

    CrossRef

  54. You have open access to this content54
    Kaori Hayashi, Satoru Motoyama, Souichi Koyota, Yukio Koizumi, Jingshu Wang, Shin Takasawa, Asako Itaya-Hironaka, Sumiyo Sakuramoto-Tsuchida, Kiyotomi Maruyama, Hajime Saito, Yoshihiro Minamiya, Jun-ichi Ogawa, Toshihiro Sugiyama, REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells, Cancer Science, 2008, 99, 12
  55. 55
    Putao Cen, Wayne L. Hofstetter, Jeffery H. Lee, William A. Ross, Tsung-Teh Wu, Stephen G. Swisher, Marta Davila, Asif Rashid, Arlene M. Correa, Jaffer A. Ajani, Value of endoscopic ultrasound staging in conjunction with the evaluation of lymphovascular invasion in identifying low-risk esophageal carcinoma, Cancer, 2008, 112, 3
  56. 56
    Jurjen J Boonstra, Winand NM Dinjens, Hugo W Tilanus, Linetta B Koppert, Molecular biological challenges in he treatment of esophageal adenocarcinoma, Expert Review of Gastroenterology & Hepatology, 2007, 1, 2, 275

    CrossRef

  57. 57
    Esophageal Adenocarcinoma,